These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30727039)

  • 1. Immunotherapy: the good, the bad, the ugly, and the really ugly.
    Branch DR
    Transfusion; 2019 Feb; 59(2):437-440. PubMed ID: 30727039
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
    Zhang J; Jin S; Guo X; Qian W
    J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microparticles: the good, the bad, and the ugly.
    Ferraris VA
    J Thorac Cardiovasc Surg; 2015 Jan; 149(1):312-3. PubMed ID: 25263714
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
    Tong B; Wang M
    Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
    Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
    Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD47 blockade as another immune checkpoint therapy for cancer.
    Vonderheide RH
    Nat Med; 2015 Oct; 21(10):1122-3. PubMed ID: 26444633
    [No Abstract]   [Full Text] [Related]  

  • 8. Cellular Bioparticulates with Therapeutics for Cancer Immunotherapy.
    Wang C; Wen D; Gu Z
    Bioconjug Chem; 2018 Mar; 29(3):702-708. PubMed ID: 29227626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of CD47 Makes Dendritic Cells See Red.
    van den Berg TK; van Bruggen R
    Immunity; 2015 Oct; 43(4):622-4. PubMed ID: 26488810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of CD47-modified biomaterials to mitigate the immune response.
    Tengood JE; Levy RJ; Stachelek SJ
    Exp Biol Med (Maywood); 2016 May; 241(10):1033-41. PubMed ID: 27190273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A; Chen J
    Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD47 checkpoint data supercharge Stanford spinout IPO.
    Dolgin E
    Nat Biotechnol; 2018 Aug; 36(8):671-672. PubMed ID: 30080839
    [No Abstract]   [Full Text] [Related]  

  • 14. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.
    Liu X; Pu Y; Cron K; Deng L; Kline J; Frazier WA; Xu H; Peng H; Fu YX; Xu MM
    Nat Med; 2015 Oct; 21(10):1209-15. PubMed ID: 26322579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
    He Y; Helfrich W; Bremer E
    Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
    Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
    Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of obesity on CD47 expression in erythrocytes.
    Wiewiora M; Piecuch J; Sedek L; Mazur B; Sosada K
    Cytometry B Clin Cytom; 2017 Nov; 92(6):485-491. PubMed ID: 25914268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.
    Zhang X; Chen W; Fan J; Wang S; Xian Z; Luan J; Li Y; Wang Y; Nan Y; Luo M; Li S; Tian W; Ju D
    Carcinogenesis; 2018 May; 39(5):689-699. PubMed ID: 29538621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD47 expression in cryopreserved equine cutaneous masses and normal skin.
    Caston SS; Cooper EE; Chandramani-Shivalingappa P; Sponseller BA; Hostetter JM; Sun Y
    J Vet Diagn Invest; 2016 Jul; 28(4):408-13. PubMed ID: 27154320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.